恩瑞格治疗铁质积聚疗效如何呢？

It is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-removing agent approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a first-line drug for patients with thalassemia iron overload over 6 years old.

So, how effective is Enrig in treating iron accumulation?

Therapeutic effects of Enrige in treating iron accumulation:

Objective: To compare the effects of Enrig and deferoxamine (DFO) in the treatment of transfusion-dependent thalassemia (TDT), and evaluate the advantages and limitations of single drug therapy.

Methods: We retrospectively analyzed the case data of TDT combined with iron overload and treated with Enrig or deferoxamine (DFO) in the outpatient clinic of our hospital from January 2013 to June 2015. Fifty-eight children in the Enrig group were treated with Enrig 20-35 mg/(kg·day), and 27 children in the deferoxamine (DFO) group were treated with deferoxamine (DFO) 25-45 mg/(kg·day), 5 days a week. The patients were followed up for 1 year since taking the medication, and serum ferritin (SF) level, liver and kidney function, and blood routine were measured every 3 to 6 months.

Results: There was no statistically significant difference in the median age, average iron intake rate and pre-treatment SF between the two groups of children.

After 6 months of follow-up, the mean SF decreases in the Enrig group and the deferoxamine (DFO) group were 168 (-2 650, 7 254) ng/mL and 170 (-260, 599) ng/mL respectively (P>0.05).

The decrease in SF in the Enrig group was positively correlated with the dose (P<0.05). After 7 to 12 months of follow-up, the mean SF decreases in the Enrig group and deferoxamine (DFO) group were 212 (-370, 795) ng/mL and -1 330 (-2 454, -206) ng/mL respectively (P < 0.05).

Conclusion: It has advantages over deferoxamine (DFO) in the treatment of TDT, and the maximum dose within the tolerance range should be used. Enrig can stabilize SF and should be used for a long time. The safe dose of deferoxamine (DFO) is not effective in children with massive blood transfusions.